149 related articles for article (PubMed ID: 21650457)
1. Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt).
Tal-Gan Y; Hurevich M; Klein S; Ben-Shimon A; Rosenthal D; Hazan C; Shalev DE; Niv MY; Levitzki A; Gilon C
J Med Chem; 2011 Jul; 54(14):5154-64. PubMed ID: 21650457
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship studies of peptidomimetic PKB/Akt inhibitors: the significance of backbone interactions.
Tal-Gan Y; Freeman NS; Klein S; Levitzki A; Gilon C
Bioorg Med Chem; 2010 Apr; 18(8):2976-85. PubMed ID: 20347317
[TBL] [Abstract][Full Text] [Related]
3. Novel method for the synthesis of urea backbone cyclic peptides using new Alloc-protected glycine building units.
Hurevich M; Tal-Gan Y; Klein S; Barda Y; Levitzki A; Gilon C
J Pept Sci; 2010 Apr; 16(4):178-85. PubMed ID: 20196085
[TBL] [Abstract][Full Text] [Related]
4. Microwave-assisted solid-phase aza-peptide synthesis: aza scan of a PKB/Akt inhibitor using aza-arginine and aza-proline precursors.
Freeman NS; Tal-Gan Y; Klein S; Levitzki A; Gilon C
J Org Chem; 2011 May; 76(9):3078-85. PubMed ID: 21410283
[TBL] [Abstract][Full Text] [Related]
5. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
Harris TK
IUBMB Life; 2003 Mar; 55(3):117-26. PubMed ID: 12822887
[TBL] [Abstract][Full Text] [Related]
6. Metabolic stability of peptidomimetics: N-methyl and aza heptapeptide analogs of a PKB/Akt inhibitor.
Tal-Gan Y; Freeman NS; Klein S; Levitzki A; Gilon C
Chem Biol Drug Des; 2011 Nov; 78(5):887-92. PubMed ID: 21824328
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.
Ashton KS; St Jean DJ; Poon SF; Lee MR; Allen JG; Zhang S; Lofgren JA; Zhang X; Fotsch C; Hungate R
Bioorg Med Chem Lett; 2011 Sep; 21(18):5191-6. PubMed ID: 21824779
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities.
Ueda S; Oishi S; Wang ZX; Araki T; Tamamura H; Cluzeau J; Ohno H; Kusano S; Nakashima H; Trent JO; Peiper SC; Fujii N
J Med Chem; 2007 Jan; 50(2):192-8. PubMed ID: 17228861
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of backbone versus side chain peptide cyclization: application for HIV-1 integrase inhibitors.
Hayouka Z; Levin A; Hurevich M; Shalev DE; Loyter A; Gilon C; Friedler A
Bioorg Med Chem; 2012 May; 20(10):3317-22. PubMed ID: 22507205
[TBL] [Abstract][Full Text] [Related]
10. Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin.
Shi YH; Song YL; Lin DH; Tan J; Roller PP; Li Q; Long YQ; Song GQ
Biochem Biophys Res Commun; 2005 May; 330(4):1254-61. PubMed ID: 15823578
[TBL] [Abstract][Full Text] [Related]
11. Sunflower trypsin inhibitor-1, proteolytic studies on a trypsin inhibitor peptide and its analogs.
Colgrave ML; Korsinczky MJ; Clark RJ; Foley F; Craik DJ
Biopolymers; 2010; 94(5):665-72. PubMed ID: 20564016
[TBL] [Abstract][Full Text] [Related]
12. Modulation of protein-ligand interactions by photocleavage of a cyclic peptide using phosphatidylinositol 3-kinase SH3 domain as model system.
Takahashi I; Kuroiwa S; Lindfors HE; Ndamba LA; Hiruma Y; Yajima T; Okishio N; Ubbink M; Hirota S
J Pept Sci; 2009 Jun; 15(6):411-6. PubMed ID: 19378350
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of backbone cyclic peptides bearing the arm domain of the HIV-1 Rev protein: characterization of the karyophilic properties and inhibition of Rev-induced gene expression.
Hariton-Gazal E; Rosenbluh J; Zakai N; Fridkin G; Brack-Werner R; Wolff H; Devaux C; Gilon C; Loyter A
Biochemistry; 2005 Aug; 44(34):11555-66. PubMed ID: 16114892
[TBL] [Abstract][Full Text] [Related]
14. The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm.
Ovadia O; Linde Y; Haskell-Luevano C; Dirain ML; Sheynis T; Jelinek R; Gilon C; Hoffman A
Bioorg Med Chem; 2010 Jan; 18(2):580-9. PubMed ID: 20056544
[TBL] [Abstract][Full Text] [Related]
15. Miniaturized proteins: the backbone cyclic proteinomimetic approach.
Kasher R; Oren DA; Barda Y; Gilon C
J Mol Biol; 1999 Sep; 292(2):421-9. PubMed ID: 10493885
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis.
Tselios T; Probert L; Daliani I; Matsoukas E; Troganis A; Gerothanassis IP; Mavromoustakos T; Moore GJ; Matsoukas JM
J Med Chem; 1999 Apr; 42(7):1170-7. PubMed ID: 10197961
[TBL] [Abstract][Full Text] [Related]
17. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.
Caldwell JJ; Davies TG; Donald A; McHardy T; Rowlands MG; Aherne GW; Hunter LK; Taylor K; Ruddle R; Raynaud FI; Verdonk M; Workman P; Garrett MD; Collins I
J Med Chem; 2008 Apr; 51(7):2147-57. PubMed ID: 18345609
[TBL] [Abstract][Full Text] [Related]
18. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
[TBL] [Abstract][Full Text] [Related]
20. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
